Sandvine Appoints Chief Ethics & Compliance Officer and Board Advisor as Part of Strengthened Commitment to Internet Freedom and Digital Rights
15.1.2025 18:41:00 CET | Business Wire | Press release
Carol Tate will serve as CCO following her tenure as Chief Compliance Officer at IntelFormer President & CEO of Human Rights First, Michael Breen, appointed as Advisor to the Board of Directors
Today, Sandvine (the “Company”), a market-leading provider of Over-the-Top (OTT) Application Classification and Quality of Experience (QoE) solutions, announced the appointments of Carol Tate as Chief Ethics & Compliance Officer, effective February 3, and Michael Breen as Advisor to the Board of Directors, effective January 1. Working closely with teams across the Company and in collaboration with its Board of Directors, Tate will spearhead compliance and due diligence initiatives to help facilitate Sandvine’s transition into a technology solution leader for democracies. Working directly with the Company’s Board of Directors, Breen is advising on human rights matters, including its engagement with non-governmental organizations to inform the Company’s human rights due diligence.
With decades of legal, risk, and compliance experience in the public and private sectors, Tate brings extensive experience embedding ethics and compliance into technological deployment and innovation on a global scale. She most recently served as Vice President and Chief Compliance Officer at Intel Corporation (NASDAQ: INTC) (“Intel”), where she led the organization’s global ethics and compliance function, which included driving initiatives to promote the company’s values and ethical culture, encourage open reporting, and reinforce Intel’s commitment to product responsibility in connection with Intel’s technology.
Prior to Intel, Tate held senior leadership roles within the ethics and compliance functions at McCarthy Holdings, Inc., Flextronics International Ltd., and Motorola. She also served as a senior attorney with the U.S. Securities and Exchange Commission’s Enforcement Division.
“As we operate in an increasingly complex digital environment, Sandvine’s focus on driving technological innovation while promoting internet freedom and digital rights could not be more critical,” said Tate. “I am excited to join a team and organization focused on providing high-quality products and premier customer service while facing these challenges head-on through close and productive partnerships with all stakeholders.”
Breen, an executive leader, strategist, policy expert and former military officer, has diverse experience leading complex organizations at the intersection of technology, global security, human rights, politics, and markets. He previously served as President & CEO of Human Rights First, a US-based organization confronting global human rights abuse, authoritarianism, and extremism through technology innovation and deployment, crisis response, policy development and advocacy, research, and legal services. Prior to leading Human Rights First, Breen acted as President & CEO of the Center for National Policy and the Truman National Security Project, served in the Obama administration’s Office of White House Counsel, and co-founded the International Refugee Assistance Project. He began his career as a decorated US Army officer, leading soldiers in combat in Iraq and Afghanistan.
“At a critical inflection point, Sandvine worked diligently to rechart its course, commit to being a positive and material contributor to the protection of human rights around the world, and double down on its mission to help people work, learn, entertain, and communicate. That resilience speaks to the Company’s potential to build itself into a values-driven technology solutions market leader,” said Breen. “I look forward to working closely with the Sandvine Board of Directors and the Company’s executive leadership team to help Sandvine navigate the challenges of today’s digital landscape.”
“Sandvine’s appointments of Carol and Michael are a direct reflection of the Company’s strengthened commitment to internet freedom and both digital and human rights, and we are honored to welcome them aboard,” added Carney Hawks, Chairman of the Board of Sandvine. “Carol’s extensive and successful track record collaborating with government and regulatory stakeholders, customers, trade groups, NGOs, and colleagues to deliver technological excellence governed by the highest ethical standards, combined with Michael’s exceptional background leading organizations dedicated to mitigating the world’s most complex issues across technology, human rights, global security and political dimensions, will be immensely valuable to Sandvine in this new chapter.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115186859/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom